Drugs for treatment of stroke, vascular dementia show promising results in early trial

news-medical | April 25, 2019

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study. The drugs - called cilostazol and isosorbide mononitrate - are already used to treat other conditions, such as heart disease and angina. This is the first time they have been tested in the UK for the treatment of stroke or vascular dementia. A study involving more than 50 stroke patients found that patients tolerated the drugs, with no serious side effects, even when the drugs were given in full dose or in combination with other medicines. Experts say the findings pave the way for larger studies to check if the treatments can prevent brain damage and reduce risk of stroke and vascular dementia. Damage to small blood vessels in the brain is responsible for around a quarter of strokes. It is also a common cause of memory problems and dementia. Around 400,000 people in the UK are affected but there are no specific treatments. Currently the only way to reduce risk of the disease is by controlling blood pressure and cholesterol, stopping smoking and managing symptoms of diabetes.

Spotlight

Merck & Co, known as MSD outside of the United States and Canada, is a global pharmaceutical company whose mission is to discover, develop and provide innovative products and services that save and improve lives around the world.


Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Spotlight

Merck & Co, known as MSD outside of the United States and Canada, is a global pharmaceutical company whose mission is to discover, develop and provide innovative products and services that save and improve lives around the world.

Resources